Treatment of Paget's disease with olpadronate. Assessment of efficacy in partial responders to pamidronate;Tratamiento de la enfermedad de Paget con olpadronato. Su eficacia terapeutica en respondedores parciales al pamidronato oral

Medicina

Volumn 57, Issue SUPPL. 1, 1997, Pages 25-31

  González, Diana ^a,b   Pastrana, Marta ^a   Mautalen, Carlos ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b Hospital de Clnicas   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; OLPADRONIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PAGET BONE DISEASE;

AGED; DIPHOSPHONATES; DRUG TOLERANCE; FEMALE; HUMANS; MALE; OSTEITIS DEFORMANS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0030820119     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Mautalen C, Pumarino H,Blanco MC, González D, Ghiringhelli G, Fromm G. Paget's disease: The South American experience. Seminars in Arthritis and Rheumatism 1994; 23:226-227.
2. Smith R, Russell RGG, Bishop M. Diphosphonates and Paget's disease of bone. Lancet 1971:1: 945-7.
3. Fromm G, Schajowicz F, Casco C, Ghiringhelli G, Mautalen C: The treatment of Paget's bone disease with sodium ethidronate. Am J Med Sci 1979; 277: 29-37.
4. Fromm G, Schajowicz F, Mautalen C. Disodium ethane-1-hydroxy-1, 1-Diphosphonate" (EHDP) in Paget's Disease. Lancet 1975; 2:666. (letter to the Editor)
5. Mautalen C, González D, Blumenfeld E, Santini Araujo E, Schajowicz F. Spontaneous fractures of uninvolved bones in patients with Paget's disease during unduly prolonged treatment with disodium etidronate (EHDP). Clin Orthop 1986; 207:150-155.
6. Mautalen C, González D, Ghiringhelli G. Efficacy of the bisphosphonate APD in the control of Paget's bone disease. Bone 1985; 6:429-432.
7. Vega E, Gonzalez D, Ghiringhelli G, Mautalen C. Intravenous aminopropylene bisphosphonate APD in the treatment of Paget's bone disease. J Bone and Min Res 1987; 2:267-271.
8. Mautalen C, Casco C, González D et al. Side effects of disodium aminohydroxy propylidene diphosphotante (APD) during treatment of bone diseases. Br Med J 1984; 288: 828-829.
9. Frijlink WB, Te Weide J, Bijvoet OLM, Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD), Lancet 1979:1:799-803.
10. Kanis JA, Mc Closkey, EV. The use of clodronate in disorders of calcium and skeletal metabolism. In: Kanis JA (ed). Calcium Metabolism. Progress in Basic and Clinical Pharmacology. Basel: Karger. 1990; Vol 4: 89-136.
11. Siris E, Weinstein R, Altman R, et al Comparative study of Alendronate versus Etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996:81: 961-967.
12. Reginster JYL. Oral tiludronate. Pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone 1992: 13: 351-354.
13. Delmas PD, Chapuy MC, Edouard C, Meunier PJ. Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am J Med 1987:83:276-282.
14. Wimalawansa SJ. Dramatic response to plicamycin in a patient with severe Paget's disease refractory to calcitonin and pamidronate. Seminars in Arthritis and Rheumatism 1994:23:267-269.
15. Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OLM. Paget's disease of bone early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 1987:295:1301-1305.
16. Hyldstrup L, Flesh G, Hauffe SA. Pharmacokinetic evaluation of pamidronate after oral administration: A study on dose proportionality, absolute bioavailability, and effect of repeated administration. Calcif Tissue Int 1993: 53:297-300.
17. Ryan PJ, Sherry M, Gibson T, Fogelman L. Treatment of Paget's disease by weekly infusions of 3-aminohydroxypropylidene-1, 1-bisphosphonate (APD), Br J Rheumatol 1991; 31:97-101.
18. Schweitzer D, Zwinderman A, Vermeis P, Bijvoet O, Papapoulos S. Improved treatment of Paget's disease with dimethyl-aminohydroxy-propylidene bisphosphonate. J Bone and Min Res 1993.8:175-182.
19. Kiviriko K, Laitinen O, Prockop O. Modifications of a specific assay for hydroxyproline in urine. Ann Biochem 1967; 19: 245-257.
20. Mautalen C. Enfermedad de Paget. Tratamiento con APD. Rev Arg Endocrinol Metab 1987;24 (Sup) 9-14.
21. Patel S, Stone MD, Coupland C, Hosking D,. Determinants of remission of Paget's Diseases of Bone. J Bone and Min Res 1993;8:1467-1473.
22. Kanis J. Drugs used for the treatment of Paget's disease. In: Kanis, JA (ed) Pathophysiology and Treatment of Paget's Disease of Bone. London: Martin Dunitz, 1991; 171.
23. Vega E, Mautalen C, Roldán EJA, Perez Lloret A. Preliminary report of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile. Drugs Exp Clin Res 1994:20:103-108.